On December 8, 2021 Hoffmann-La Roche reported that invite investors and analysts to participate in our virtual event on Wednesday, 15 December, 2021, highlighting Roche data presented at the virtual American Society of Hematology (ASH) (Free ASH Whitepaper) 63rd Annual Meeting, from 11-14th December (Press release, Hoffmann-La Roche, DEC 8, 2021, View Source [SID1234596593]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

16:00 – 17:30 CET / 15:00 – 16:30 GMT
10:00 – 11:30 am EST / 7:00 – 8:30 am PST

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers).

Agenda:

Welcome
Karl Mahler, Head of Investor Relations

Hematology franchise overview
Peter Ahnesorg, Franchise Head Hematology

Review of key clinical data presented at ASH (Free ASH Whitepaper): Hemlibra, mosun, glofit, cevostamab
Charles Fuchs, Senior Vice President – Global Head Of Oncology And Hematology Product Development

Presentation of POLARIX data
Franck Morschhauser, MD, PhD, Professor of Hematology, University of Lille; President of LYSA, LYSARC

Q&A

The slides will be available for download at 15:00 CET on the day of the event. > click here

Should you be unable to register for the webinar due to your company IT policy, please send an email to [email protected].